Center for Outcomes Research, Saint Louis University School of Medicine, St. Louis, MO, USA; Division of Infectious Diseases, Washington University in St. Louis School of Medicine, St. Louis, MO, USA.
Clin Transplant. 2013 Sep-Oct;27(5):E554-62. doi: 10.1111/ctr.12198. Epub 2013 Aug 1.
We sought to assess the disutility associated with diabetes in the kidney transplant population.
We enrolled 233 kidney transplant recipients age 18-74 from a Midwestern hospital outpatient department. Recipients with multiple or multi-organ transplants, those with laboratory evidence that suggests acute cellular damage (creatinine-kinase > 200 U/L), or a diagnosis of acute renal failure or acute rejection were excluded from the analysis (n = 33). Participants health-related quality of life (HRQOL) were evaluated using the Euro-QoL-5 Dimension (EQ-5D), Health Utility Index Mark III (HUI-III), and the Short Form-6D (SF-6D), which was calculated from the generic section (SF-12) of the Kidney Disease Quality of Life 36 (KDQOL-36). We estimated health utilities associated with diabetes using general linear modeling after adjusting for demographic, socioeconomic, and clinical characteristics.
The adjusted health disutilities associated with diabetes were clinically and statistically significant: EQ-5D (Δ = 0.05; p < 0.01), HUI-III (Δ = 0.09; p < 0.01), and SF-6D (Δ = 0.04, p < 0.01). There was no difference between diabetic patients with good glycemic control (mean serum glucose <126 mg/dL in the three months prior to enrollment) and patients with poor glycemic control.
Among kidney transplant patients between the ages of 18-74, non-diabetics have significantly higher HRQOL scores on the EQ-5D, HUI-III, and SF-6D compared with patients with diabetes.
评估糖尿病在肾移植受者中的不良影响。
我们纳入了来自中西部医院门诊的 233 名年龄在 18-74 岁之间的肾移植受者。排除了有多器官或多器官移植的受者、实验室检查提示急性细胞损伤(肌酸激酶>200U/L)的受者,或有急性肾衰竭或急性排斥反应诊断的受者(n=33)。使用欧洲五维健康量表(EQ-5D)、健康效用指数 3 版(HUI-III)和简易 6 维度量表(SF-6D)评估参与者的健康相关生活质量(HRQOL),SF-6D 由肾脏病生活质量 36 项(KDQOL-36)的通用部分(SF-12)计算得出。我们调整了人口统计学、社会经济学和临床特征后,使用广义线性模型估计与糖尿病相关的健康效用。
与糖尿病相关的调整后健康不良影响具有临床和统计学意义:EQ-5D(Δ=0.05;p<0.01)、HUI-III(Δ=0.09;p<0.01)和 SF-6D(Δ=0.04,p<0.01)。血糖控制良好(入组前三个月平均血清葡萄糖<126mg/dL)的糖尿病患者和血糖控制不佳的患者之间没有差异。
在 18-74 岁的肾移植患者中,与糖尿病患者相比,非糖尿病患者在 EQ-5D、HUI-III 和 SF-6D 上具有显著更高的 HRQOL 评分。